Replimune Group Gross Profit

Replimune Group (REPL) currently reports a gross profit of $-3.3M as of March 2026. That compares with $740K in the prior-year period — down 550.3% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Replimune Group's gross profit history and peer comparisons.

Replimune Group's gross profit decreased from $740K to $-3.3M — a 550.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Replimune Group's gross profit of $-3.3M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Replimune Group reported $-3.3M in gross profit as of March 2026. That compares with $740K in the prior-year period — down 550.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-3.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Replimune Group, and consider following REPL for alerts when major investors trade the stock.